NCT05305508 - Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

November 10, 2023

Study Completion Date

February 5, 2024

Conditions

COVID-19 Virus Disease

Interventions

DRUG

Calcium Dobesilate

The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.

DRUG

Mannitol

The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.

Trial Locations (1)

Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva